Positions

Overview

  • Dr. Nabors, originally from Columbus, Mississippi, obtained his Bachelor of Science degree in Engineering from Mississippi State University in 1985. He then obtained his Medical Doctorate from the University of Tennessee in 1991. Dr. Nabors was active in the United States Navy as a Flight Surgeon from 1992-95. Afterwards, he completed a Neuro-oncology fellowship at the University of Alabama at Birmingham in 2000 and is board certified with the American Board of Psychiatry and Neurology.

    Dr. Nabors is currently Professor and Vice-Chair of Research of Neurology and Director for the UAB Division of Neuro-oncology. He is an active participating member of the medical staff with the Neurology Service for UAB Hospital and an Associate Scientist in the Neuro-oncology Program at the UAB Comprehensive Cancer Center. He has secondary appointments with the Department of Biomedical Engineering and the Department of Cell Biology. He is the Director of UAB’s Center for Clinical Translational Science’s Clinical Research Unit.

    Dr. Nabors’ subspecialty is Neuro-Oncology, the main focus of which is the Comprehensive Cancer Center Neuro-Oncology Program, which consists of Neuro-oncology, Neurosurgery, Radiation Oncology, Neuropathology, Research Scientists, Nurse Practitioners, and Neuropsychologists.

    Medical therapy is an integral part of treatment for patients with brain tumors and includes conventional chemotherapy as well as the use of novel, experimental therapies that are designed to destroy tumors that cannot be removed by surgery or radiation therapy. Dr. Nabors oversees this part of the treatment plan for patients with brain tumors. In addition, he takes care of the medical and neurologic problems that many patients with brain tumors develop, including seizures, infections, and emotional problems.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 Letter: When less is more: Dexamethasone dosing for brain tumorsNeurosurgery.  85:E607-E608. 2019
    2019 Anti-cancer effects of the HuR inhibitor, MS-444, in malignant glioma cellsCancer Biology and Therapy.  20:979-988. 2019
    2019 Diagnosing growth in low-grade gliomas with and without longitudinal volume measurements: A retrospective observational studyPLoS Medicine.  16. 2019
    2019 Management of Central Nervous System TumorsJournal of the National Comprehensive Cancer Network.  17:579-582. 2019
    2019 An early feasibility study of the Nativis Voyager ® device in patients with recurrent glioblastoma: first cohort in USCNS Oncology.  8:CNS30. 2019
    2019 Glioma risk associated with extent of estimated European genetic ancestry in African Americans and HispanicsInternational Journal of Cancer2019
    2019 MGMT promoter methylation cutoff with safety margin for selecting glioblastoma patients into trials omitting temozolomide: A pooled analysis of four clinical trialsClinical Cancer Research.  25:1809-1816. 2019
    2019 Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR -amplified, recurrent glioblastoma: Results from an international phase I multicenter trialNeuro-Oncology.  21:106-114. 2019
    2018 Associations of anticoagulant use with outcome in newly diagnosed glioblastomaEuropean journal of cancer.  101:95-104. 2018
    2018 Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma.Clinical Cancer Research.  25:73-79. 2018
    2018 Toenail selenium, genetic variation in selenoenzymes and risk and outcome in gliomaCancer Detection and Prevention.  55:45-51. 2018
    2018 Activation of the receptor tyrosine kinase AXL regulates the immune microenvironment in glioblastomaCancer Research.  78:3002-3013. 2018
    2018 Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?Journal of Neuro-Oncology.  138:163-171. 2018
    2018 Handedness and the risk of gliomaJournal of Neuro-Oncology.  137:639-644. 2018
    2017 Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international studyCancer Chemotherapy and Pharmacology.  80:1209-1217. 2017
    2017 The use of cannabidiol for seizure management in patients with brain tumor-related epilepsyNeurocase.  23:287-291. 2017
    2017 Central nervous system cancers, version 1.2017 featured updates to the NCCN guidelinesJournal of the National Comprehensive Cancer Network.  15:1331-1345. 2017
    2017 Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trialLancet Oncology.  18:1373-1385. 2017
    2017 Implementation and utilization of the molecular tumor board to guide precision medicine.Oncotarget.  8:57845-57854. 2017
    2017 When less is better: Care of the elderly with glioblastomaNeuro-Oncology.  19:879. 2017
    2017 Older age at the completion of linear growth is associated with an increased risk of adult gliomaCancer Causes and Control.  1-8. 2017
    2017 Repeatability of 18F-FLT PET in a multicenter study of patients with high-grade gliomaJournal of Nuclear Medicine.  58:393-398. 2017
    2017 Hu antigen R (HuR) multimerization contributes to glioma disease progressionJournal of Biological Chemistry.  292:16999-17010. 2017
    2017 Implementation and utilization of the molecular tumor board to guide precision medicineOncotarget.  8:57845-57854. 2017
    2017 Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomasNeuro-Oncology.  19:845-852. 2017
    2016 Primary Sellar Rhabdomyosarcoma Arising in Association with a Pituitary AdenomaInternational Journal of Surgical Pathology.  24:753-756. 2016
    2016 Analgesic use and the risk of primary adult brain tumorEuropean Journal of Epidemiology.  31:917-925. 2016
    2016 Reply to F. Felix et al and M.F. Fay et alJournal of Clinical Oncology.  34:3107-3108. 2016
    2016 Pilot Study to Explore the Accuracy of Current Prediction Equations in Assessing Energy Needs of Patients with Newly Diagnosed Glioblastoma MultiformeNutrition and Cancer.  68:926-934. 2016
    2016 Design of a Phase i Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or GliosarcomaHuman Gene Therapy Clinical Development.  27:69-78. 2016
    2016 Central nervous system: Notable developments in the management of primary and recurrent gliomasJournal of the National Comprehensive Cancer Network.  14:681-684. 2016
    2016 Cilengitide in newly diagnosed glioblastoma: Biomarker expression and outcomeOncotarget.  7:15018-15032. 2016
    2016 Does valproic acid or levetiracetam improve survival in glioblastoma? A pooled analysis of prospective clinical trials in newly diagnosed glioblastomaJournal of Clinical Oncology.  34:731-739. 2016
    2016 Complications from pharmacotherapyHandbook of Clinical Neurology.  134:235-250. 2016
    2015 Capacity of patients with brain metastases to make treatment decisionsPSYCHO-ONCOLOGY.  24:1448-1455. 2015
    2015 Central Nervous System Cancers, Version 1.2015.Journal of the National Comprehensive Cancer Network.  13:1191-1202. 2015
    2015 Central nervous system cancers, version 1.2015: Featured updates to the NCCN guidelinesJournal of the National Comprehensive Cancer Network.  13:1191-1202. 2015
    2015 Evaluation of the safety and benefit of phase I oncology trials for patients with primary CNS tumorsJournal of Clinical Oncology.  33:3186-3192. 2015
    2015 Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomasJournal of Neuro-Oncology.  125:123-131. 2015
    2015 Cognitive Predictors of Reasoning through Treatment Decisions in Patients with Newly Diagnosed Brain MetastasesJournal of the International Neuropsychological Society.  21:412-418. 2015
    2015 Ipilimumab-induced encephalopathy with a reversible splenial lesionCancer Immunology Research.  3:598-601. 2015
    2015 Prolonged treatment with bevacizumab is associated with brain atrophy: a pilot study in patients with high-grade gliomasJournal of Neuro-Oncology.  122:585-593. 2015
    2015 Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: Results of the open-label, controlled, randomized phase II CORE studyNeuro-Oncology.  17:708-717. 2015
    2015 Growth factor dependent regulation of centrosome function and genomic instability by HuRBiomolecules.  5:263-281. 2015
    2015 Brain tumor risk according to germ-line variation in the MLLT10 locusEuropean Journal of Human Genetics.  23:132-134. 2015
    2015 Complementary therapy and survival in glioblastomaNeuro Oncology Practice.  2:122-126. 2015
    2015 Impairment of medical decisional capacity in relation to Karnofsky Performance Status in adults with malignant brain tumorNeuro Oncology Practice.  2:13-19. 2015
    2015 Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastomaNeuro-Oncology.  17:430-439. 2015
    2015 SLC7A1 expression is associated with seizures, predicts poor survival in patients with malignant gliomaScience Translational Medicine.  7. 2015
    2014 Hypofractionated stereotactic radiosurgery with concurrent bevacizumab for recurrent malignant gliomas: The University of Alabama at Birmingham experienceNeuro Oncology Practice.  1:172-177. 2014
    2014 Central nervous system cancers, Version 2.2014: Featured updates to the NCCN guidelinesJournal of the National Comprehensive Cancer Network.  12:1517-1523. 2014
    2014 Role of MRI in primary brain tumor evaluationJournal of the National Comprehensive Cancer Network.  12:1561-1568. 2014
    2014 Cognition in patients with newly diagnosed brain metastasis: Profiles and implicationsJournal of Neuro-Oncology.  120:179-185. 2014
    2014 The role of bevacizumab in glioblastomaJournal of the National Comprehensive Cancer Network.  12:1201-1202. 2014
    2014 A phase 1 trial of oncolytic HSV-1, g207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responsesMolecular Therapy.  22:1048-1055. 2014
    2014 Circadian pathway genes in relation to glioma risk and outcomeCancer Causes and Control.  25:25-32. 2014
    2014 Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitroJournal of Neuro-Oncology.  118:61-72. 2014
    2014 Reproductive factors and risk of primary brain tumors in womenJournal of Neuro-Oncology.  118:297-304. 2014
    2014 Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parametersJournal of Neuro-Oncology.  120:361-370. 2014
    2014 The role of Src family kinases in growth and migration of glioma stem cellsInternational Journal of Oncology.  45:302-310. 2014
    2013 Toenail iron, genetic determinants of iron status, and the risk of gliomaCancer Causes and Control.  24:2051-2058. 2013
    2013 Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastomaJournal of Clinical Oncology.  31:3212-3218. 2013
    2013 Central nervous system cancersJournal of the National Comprehensive Cancer Network.  11:1114-1151. 2013
    2013 Prediagnostic body weight and survival in high grade gliomaJournal of Neuro-Oncology.  114:79-84. 2013
    2013 Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated O(6)-methylguanine-DNA methyltransferase (MGMT) gene promoter: Key results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study.Journal of Clinical Oncology.  31:LBA2009. 2013
    2013 Mutant tristetraprolin: A potent inhibitor of malignant glioma cell growthJournal of Neuro-Oncology.  113:195-205. 2013
    2013 Early life exposures and the risk of adult gliomaEuropean Journal of Epidemiology.  28:753-758. 2013
    2013 Anthropometric factors in relation to risk of gliomaCancer Causes and Control.  24:1025-1031. 2013
    2013 NABTT 0502: A phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiformeNeuro-Oncology.  15:490-496. 2013
    2013 SWI/SNF gene variants and glioma risk and outcomeCancer Detection and Prevention.  37:162-165. 2013
    2013 A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant gliomaClinical Cancer Research.  19:900-908. 2013
    2012 A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306)Cancer.  118:5601-5607. 2012
    2012 Erratum: An exploratory analysis of common genetic variants in the vitamin D pathway including genome-wide associated variants in relation to glioma risk and outcome (Cancer Causes Control DOI:10.1007/s10552-012-0018-7)Cancer Causes and Control.  23:1745. 2012
    2012 Phosphoregulation of the RNA-binding protein Hu antigen R (HuR) by Cdk5 affects centrosome functionJournal of Biological Chemistry.  287:32277-32287. 2012
    2012 Primary central nervous system angiosarcoma: Two case reportsJournal of Medical Case Reports.  6. 2012
    2012 Rare TP53 genetic variant associated with glioma risk and outcomeJournal of Medical Genetics.  49:420-421. 2012
    2012 SSBP2 variants are associated with survival in glioblastoma patientsClinical Cancer Research.  18:3154-3162. 2012
    2012 Sex hormone-dependent attenuation of EAE in a transgenic mouse with astrocytic expression of the RNA regulator HuRJournal of Neuroimmunology.  246:34-37. 2012
    2012 An exploratory analysis of common genetic variants in the vitamin D pathway including genome-wide associated variants in relation to glioma risk and outcomeCancer Causes and Control.  23:1443-1449. 2012
    2011 A functional polymorphism in the pre-miR-146a gene is associated with risk and prognosis in adult gliomaJournal of Neuro-Oncology.  105:639-646. 2011
    2011 Phase I trial of sorafenib in patients with recurrent or progressive malignant gliomaNeuro-Oncology.  13:1324-1330. 2011
    2011 Phase i and pharmacokinetic study of COL-3 in patients with recurrent high-grade gliomasJournal of Neuro-Oncology.  105:375-381. 2011
    2011 Erratum: Cancer susceptibility variants and the risk of adult glioma in a US case-control study (Journal of Neuro-Oncology DOI: 10.1007/s11060-010-0506-0)Journal of Neuro-Oncology.  104:543. 2011
    2011 A phase II study of daily afatinib (BIBW 2992) with or without temozolomide (21/28 days) in the treatment of patients with recurrent glioblastoma.Journal of Clinical Oncology.  29:2010. 2011
    2011 The RNA-binding protein HuR promotes glioma growth and treatment resistanceCell Growth and Differentiation.  9:648-659. 2011
    2011 Central nervous system cancers: Clinical practice guidelines in oncologyJournal of the National Comprehensive Cancer Network.  9:352-400. 2011
    2011 Cilengitide: An RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignanciesFuture Oncology.  7:339-354. 2011
    2011 Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomideAustralasian Radiology.  55:77-81. 2011
    2011 Cancer susceptibility variants and the risk of adult glioma in a US case-control studyJournal of Neuro-Oncology.  104:535-542. 2011
    2010 Treatment of primary CNS lymphoma with high-dose methotrexate in immunocompetent pediatric patientsMedical and Pediatric Oncology.  55:1227-1230. 2010
    2010 Phase 1 clinical trial of bortezomib in adults with recurrent malignant gliomaJournal of Neuro-Oncology.  100:95-103. 2010
    2010 Integrins-a relevant target in glioblastomaEuropean journal of clinical & medical oncology.  2. 2010
    2010 Targeting integrins in malignant gliomaTargeted Oncology.  5:175-181. 2010
    2010 Capacity to consent to research participation in adults with malignant gliomaJournal of Clinical Oncology.  28:3844-3850. 2010
    2010 Rationally designed pharmacogenomic treatment using concurrent capecitabine and radiotherapy for glioblastoma; gene expression profiles associated with outcomeClinical Cancer Research.  16:2890-2898. 2010
    2010 Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United StatesClinical Cancer Research.  16:2443-2449. 2010
    2010 A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastomaArchives of Neurology -Chigago-.  67:313-319. 2010
    2009 Amyotrophic lateral sclerosis-linked mutant SOD1 sequesters Hu antigen R (HuR) and TIA-1-related protein (TIAR). Implications for impaired post-transcriptional regulation of vascular endothelial growth factorJournal of Biological Chemistry.  284:33989-33998. 2009
    2009 Characterization and immunotherapeutic potential of γδ T-cells in patients with glioblastomaNeuro-Oncology.  11:357-367. 2009
    2009 Distress and quality of life in primary high-grade brain tumor patientsSupportive Care in Cancer.  17:793-799. 2009
    2009 Will integrin inhibitors have proangiogenic effects in the clinic?Nature Medicine.  15:726. 2009
    2009 A phase I evaluation of intravenous (IV) (131)I-chlorotoxin delivery to solid peripheral and intracranial tumors.Journal of Clinical Oncology.  27:e14507. 2009
    2009 A phase I evaluation of intravenous TM601 in recurrent glioblastoma: Use of perfusion MRI to monitor antiangiogenic effects.Journal of Clinical Oncology.  27:2041. 2009
    2009 A phase I study of ABT 510 and concurrent temozolamide and radiotherapy for patients with newly diagnosed glioblastoma multiforme.Journal of Clinical Oncology.  27:2023. 2009
    2009 Current survival statistics for patients with newly diagnosed glioblastoma treated with radiation and temozolomide on research studies in the United States.Journal of Clinical Oncology.  27:2003. 2009
    2009 Dosimetry study of a phase II multiple-dose intracavitary administration of (131)I-TM601 in adult patients with recurrent high-grade glioma.Journal of Clinical Oncology.  27:e13006. 2009
    2009 Feasibility and phase I trial of tandutinib in patients with recurrent glioblastoma.Journal of Clinical Oncology.  27:2039. 2009
    2009 NABTT 0306: A randomized phase II trial of EMD 121974 in conjunction with concomitant and adjuvant temozolomide with radiation therapy in patients with newly diagnosed glioblastoma multiforme (GBM).Journal of Clinical Oncology.  27:2001. 2009
    2009 NABTT-0702: A phase II study of R-(-)-gossypol (AT-101) in recurrent glioblastoma multiforme (GBM).Journal of Clinical Oncology.  27:2010. 2009
    2009 Treatment of recurrent malignant glioma with G207, a genetically engineered herpes simplex virus-1, followed by irradiation: Phase I study results.Journal of Clinical Oncology.  27:2042. 2009
    2009 Isolated central nervous system posttransplant lymphoproliferative disorder treated with high-dose intravenous methotrexateAmerican Journal of Transplantation.  9:1243-1248. 2009
    2009 High-resolution longitudinal assessment of flow and permeability in mouse glioma vasculature: Sequential small molecule and SPIO dynamic contrast agent MRIMagnetic Resonance in Medicine.  61:615-625. 2009
    2009 Medical decision-making capacity in patients with malignant gliomaNeurology.  73:2086-2092. 2009
    2009 Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBMMolecular Therapy.  17:199-207. 2009
    2008 Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiformeJournal of Clinical Oncology.  26:5610-5617. 2008
    2008 The ING4 tumor suppressor attenuates NF-κB activity at the promoters of target genesMolecular and Cellular Biology.  28:6632-6645. 2008
    2008 Cilengitide: An integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiformeExpert Opinion on Investigational Drugs.  17:1225-1235. 2008
    2008 Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: Implications for STAT-3 activation and gene expressionClinical Cancer Research.  14:4694-4704. 2008
    2008 Phase i and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomasNeuro-Oncology.  10:608-616. 2008
    2008 Central nervous system cancers.Journal of the National Comprehensive Cancer Network.  6:456-504. 2008
    2008 Central nervous system cancers: Clinical Practice Guidelines in Oncology™Journal of the National Comprehensive Cancer Network.  6:456-504. 2008
    2007 Phase I and correlative biology study of cilengitide in patients with recurrent malignant gliomaJournal of Clinical Oncology.  25:1651-1657. 2007
    2007 ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesisCancer Biology and Therapy.  6:454-462. 2007
    2006 Increased expression of thymidylate synthetase (TS), ubiquitin specific protease 10 (USP10) and survivin is associated with poor survival in glioblastoma multiforme (GBM)Journal of Neuro-Oncology.  80:261-274. 2006
    2006 1p/19q chromosome deletions in metastatic oligodendrogliomaJournal of Neuro-Oncology.  80:203-207. 2006
    2006 Case report of a patient with primary central nervous system lymphoma treated with radioimmunotherapyClinical lymphoma.  7:236-238. 2006
    2006 Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade gliomaJournal of Clinical Oncology.  24:3644-3650. 2006
    2006 Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: Results of North Central Cancer Treatment Group protocol N0177International Journal of Radiation Oncology - Biology - Physics.  65:1192-1199. 2006
    2006 Safety and tolerance of multiple weekly intracavitary injections of 131I-chlorotoxin (TM-601): Preliminary results of a prospective clinical trial in patients with recurrent glioblastoma multiforme.Journal of Clinical Oncology.  24:1555. 2006
    2006 A novel technique to quantify glioma tumor invasion using serial microscopy sectionsJournal of Neuroscience Methods.  153:183-189. 2006
    2005 The ELAV RNA-stability factor HuR binds the 5′-untranslated region of the human IGF-IR transcript and differentially represses cap-dependent and IRES-mediated translationNucleic Acids Research.  33:2962-2979. 2005
    2005 Lyn kinase activity is the predominant cellular Src kinase activity in glioblastoma tumor cellsCancer Research.  65:5535-5543. 2005
    2005 Treatment of adults with recurrent malignant gliomaExpert Review of Neurotherapeutics.  5:509-514. 2005
    2005 IL-1β induces stabilization of IL-8 mRNA in malignant breast cancer cells via the 3′ untranslated region: Involvement of divergent RNA-binding factors HuR, KSRP and TIARInternational Journal of Cancer.  113:911-919. 2005
    2004 Assessment of brain tumor angiogenesis inhibitors using perfusion magnetic resonance imaging: Quality and analysis results of a phase I trialJournal of Magnetic Resonance Imaging.  20:913-922. 2004
    2004 A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant settingMolecular Therapy.  10:958-966. 2004
    2004 Treatment of relapsed central nervous system lymphoma with high-dose methotrexateClinical Cancer Research.  10:5643-5646. 2004
    2004 Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: Final report of NABTT 97-11Neuro-Oncology.  6:21-27. 2004
    2004 Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11.Neuro-Oncology.  6:21-27. 2004
    2004 Prognostic Value of 1p, 19q, 9p, 10q, and EGFR-FISH Analyses in Recurrent OligodendrogliomasJournal of Neuropathology and Experimental Neurology.  63:314-322. 2004
    2004 Targeted molecular therapy for malignant gliomasCurrent Treatment Options in Oncology.  5:519-526. 2004
    2003 Tumor necrosis factor α induces angiogenic factor up-regulation in malignant glioma cells: A role for RNA stabilization and HuRCancer Research.  63:4181-4187. 2003
    2002 Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: Implications for a dual modality treatment using capecitabine and irradiationMolecular Cancer Therapeutics.  1:1139-1145. 2002
    2002 Human cytomegalovirus infection and expression in human malignant gliomaCancer Research.  62:3347-3350. 2002
    2001 Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells.Journal of Clinical Investigation.  108:1657-1665. 2001
    2001 HuR, a RNA stability factor, is expressed in malignant brain tumors and binds to adenine- and uridine-rich elements within the 3′ untranslated regions of cytokine and angiogenic factor mRNAsCancer Research.  61:2154-2161. 2001
    2001 Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cellsJournal of Clinical Investigation.  108:1657-1665. 2001
    2000 Analysis of the 5' end of the mouse Elavl1 (mHuA) gene reveals a transcriptional regulatory element and evidence for conserved genomic organizationGene.  242:125-131. 2000
    1999 Hu antigen specificities of ANNA-I autoantibodies in paraneoplastic neurological diseaseJournal of Autoimmunity.  13:435-443. 1999
    1998 HuR, a novel target of anti-Hu antibodies, is expressed in non-neural tissuesJournal of Neuroimmunology.  92:152-159. 1998
    1997 Magnetic resonance cisternography in the diagnosis of delayed iatrogenic cerebrospinal fistula: A case reportJournal of Neuroimaging.  7:244-247. 1997
    1991 A unique neuronal organization in the cat pretectum revealed by antibodies to the calcium-binding protein calbindin-D 28KJournal of Neuroscience.  11:2460-2476. 1991
    1988 Quantitative immunocytochemistry using an image analyzer. I. Hardware evaluation, image processing, and data analysisJournal of Neuroscience Methods.  26:1-23. 1988
    1988 Quantitative immunocytochemistry using an image analyzer. II. Concentration standards for transmitter immunocytochemistryJournal of Neuroscience Methods.  26:25-34. 1988

    Chapter

    Year Title Altmetric
    2012 Primary Melanotic Tumors of the Central Nervous System.  709-714. 2012

    Research Overview

  • I maintain an active laboratory and translational research program focused on the role of RNA binding proteins in cancer and advancing basic science observations into meaningful clinical trials for patients.

    Research interest is focused into three main areas: The first is a basic effort to understand the role post-transcriptional processes play in cancer initiation and progression. The second area of research interest takes advantage of my engineering background and appointment in the School of Engineering.
    The third area of interest is the logical extension of the first two for a physician-scientist and involves the early phase clinical evaluation of novel cancer therapies. This includes the design and implementation of trials for newly diagnosed and recurrent malignant glioma that utilize biologically targeted strategies and includes non-invasive endpoints in the evaluation of a biological effect.
  • Principal Investigator On

  • NCI-CONNECT (Comprehensive Oncology Network Evaluating Rare CNS Tumors) Collaborative Agreement  awarded by National Cancer Institute/NIH/DHHS 2019 - 2024
  • A Pilot Study of Voraxaze(glucarpidase) in Patients with Central Nervous System Lymphoma  awarded by Memorial Sloan-Kettering Cancer Center 2019 - 2024
  • Brain Tumor Trials Collaborative Agreement  awarded by NIH - National Institutes of Health/DHHS 2019 - 2024
  • Network of Excellence in Neuroscience Clinical Trials (NEXT)  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2018 - 2023
  • Comprehensive Cancer Center Core Support Grant - Neuro-Oncology Program  awarded by National Cancer Institute/NIH/DHHS 2019 - 2021
  • Individualized Screening Trial of Innovative Glioblastoma Therapy (Insight)  awarded by Dana-Farber Cancer Institute 2019 - 2020
  • Cytoplasmic Multimerization of the RNA-Binding Protein HuR is Oncogenic in Glioma  awarded by National Cancer Institute/NIH/DHHS 2015 - 2020
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2014 - 2020
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2016 - 2020
  • Individualized Screening trial of Innovative Glioblastoma Therapy (INSIGhT)  awarded by Dana-Farber Cancer Institute 2018 - 2020
  • Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients with Recurrent High Grade Glioma  awarded by Johns Hopkins University 2018 - 2020
  • A Phase I and Pilot Study of the Effect of rhIL-7-hyFc (NT-I7) on CD4 Counts in Patients with High Grade Gliomas and Severe Treatment-Related CD4 Lymphopenia after Concurrent Radiation and Temozolomide  awarded by Johns Hopkins University 2018 - 2020
  • Single-arm, Open-label Phase II Efficacy Study of First-in-class HIF2-Alpha Inhibitor, PT2385, for Patients with Recurrent Glioblastoma  awarded by Johns Hopkins University 2017 - 2020
  • Phase I Study to Determine the Safety and Tolerability of the Oral Microtubule Destabilizer BAL 101553 in Combination with Standard Radiation in Patients with MGMT Promoter Unmethylated Newly Diagnosed Glioblastoma  awarded by Johns Hopkins University 2017 - 2020
  • Adult Brain Tumor Consortium  awarded by Johns Hopkins University 2014 - 2020
  • Phase I Study of MK-1775 with Radiation and Temozolomide In Patients with Newly Diagnosed Glioblastoma and Evaluation of lntratumoral Drug Distribution in Patients with Recurrent Glioblastoma  awarded by Johns Hopkins University 2013 - 2019
  • A Phase I/II Trial of Hydroxychloroquine in Conjunction with Radiation Therapy and Concurrent and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (Therapeutics Studies of Anaplastic Glioma)  awarded by Johns Hopkins University 2011 - 2019
  • Private Grant  awarded by STEMLINE THERAPEUTICS INC 2014 - 2019
  • Private Grant  awarded by NATIVIS, INC. 2015 - 2019
  • A Phase I Trial of Anti-LAG-3 or Anti-CD137 Alone and in Combination with Anti-PD-1 in Patients with Recurrent GBM  awarded by Johns Hopkins University 2016 - 2019
  • Sequence Variation in MtDNA and Extreme Survival in Glioblastoma  awarded by H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE 2017 - 2019
  • Comprehensive Cancer Center Core Support Grant - Neuro-Oncology Program  awarded by National Cancer Institute/NIH/DHHS 2017 - 2019
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2017 - 2019
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2017 - 2019
  • Private Grant  awarded by ORBUS THERAPEUTICS, INC. 2016 - 2018
  • A Phase I Open Label Safety Study to Evaluate the Pharmacokinetic Profile and Tolerance of Mibefradil Dose Finding in Subjects with Recurrent High-Grade Glioma Undergoing Standard. Repeated Temozolomide Treatment (TAU-2010-1)  awarded by Johns Hopkins University 2013 - 2018
  • Private Grant  awarded by ARCHER BIOSCIENCES 2013 - 2018
  • Phase I/II Study of the Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients with Newly Diagnosed Malignant Glioma  awarded by Johns Hopkins University 2012 - 2018
  • The Effect of IL-7 (CYT107) on CD4 Counts in Patients with High Grade Gliomas and Severe Treatment-Related CD4 Lymphopenia after Concurrent Radiation and Temozolomide  awarded by Johns Hopkins University 2016 - 2018
  • Refinement and Expansion of the Palliative Care Research Cooperative Group (PCRC)  awarded by Duke University 2017 - 2018
  • Network of Excellence in Neuroscience Clinical Trials (NEXT)  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2011 - 2018
  • Private Grant  awarded by ABBVIE INC 2015 - 2018
  • Phase II Study of TRC102 in Combination with Temozolomide for Recurrent Glioblastoma  awarded by Johns Hopkins University 2016 - 2018
  • Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients with Recurrent High Grade Glioma (ABTC 1401)  awarded by Johns Hopkins University 2015 - 2018
  • Private Grant  awarded by ABBVIE INC 2017 - 2018
  • Contemporary Therapeutics for Anaplastic Gliomas - Clinical Trials Core  awarded by National Cancer Institute/NIH/DHHS 2011 - 2017
  • Pilot Study of MLN0128 in Preoperative Recurrent Glioblastoma (GBM) Patients  awarded by Johns Hopkins University 2014 - 2016
  • Private Grant  awarded by St. Jude Medical 2014 - 2016
  • Private Grant  awarded by CELLDEX THERAPEUTICS, INC. 2012 - 2016
  • Private Grant  awarded by ARCHER BIOSCIENCES 2014 - 2015
  • Private Grant  awarded by ELI LILLY AND COMPANY 2012 - 2015
  • Private Grant  awarded by CELLDEX THERAPEUTICS, INC. 2012 - 2015
  • An Open Label, Phase 2 Study Evaluating the Safety and Efficacy of IMC-3G3 or IMC-1121B in Patients with Recurrent Glioblastoma Mutiforme  awarded by Johns Hopkins University 2011 - 2014
  • A Phase lb Study of Cediranib in Combination with Cilengitide in Patients with Recurrent Glioblastoma  awarded by Johns Hopkins University 2010 - 2014
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2013 - 2014
  • Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH-ll): A Phase III Randomized Multicenter Clinical Trial of Blood Pressure Reduction  awarded by University of Minnesota 2013 - 2014
  • A Pilot Phase IIB, Randomized, Multi-Center Trial of Argatroban in Combination with Recombinant Tissue Plasminogen Activator for Acute Stroke (ARTSS-2)  awarded by UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER (HOUSTON) 2014
  • N0874: Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients with Newly Diagnosed Glioblastoma  awarded by Johns Hopkins University 2012 - 2013
  • Private Grant  awarded by EMD SERONO 2009 - 2013
  • Private Grant  awarded by EMD SERONO 2009 - 2013
  • Southeast Region Case-Control Study of Adult Glioma  awarded by H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE 2007 - 2012
  • Phase I/II Trial of Temozolomide and ABT-888 in Subjects with Newly Diagnosed  awarded by Johns Hopkins University 2010 - 2012
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2009 - 2012
  • Private Grant  awarded by ASTRAZENECA INTERNATIONAL 2009 - 2011
  • A Feasibility Assessment and a Phase I/II Trial of MLN518 for Treatment of Patients with Recurrent Glioblastoma  awarded by Johns Hopkins University 2010 - 2011
  • Molecular Therapeutics for Anaplastic Gliomas - Core C  awarded by National Cancer Institute/NIH/DHHS 2005 - 2011
  • Post-Transcriptional Regulation Requires Phosphorylation of HuR in Gliomas  awarded by National Cancer Institute/NIH/DHHS 2006 - 2010
  • Private Grant  awarded by EMD PHARMACEUTICALS, INC. 2004 - 2010
  • Investigator On

  • Private Grant  awarded by PUMA BIOTECHNOLOGY, INC. 2019 - 2024
  • Center for Clinical and Translational Science (3 Linked Awards UL1, KL2, TL1)  awarded by National Center for Advancing Translational Sciences/NIH/DHHS 2019 - 2024
  • Radiation-Induced Crosstalk of Immune and Glioma Stem Cells  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2019 - 2024
  • TBCRC 049 UAB 1794: A Phase II Non-randomized Study to Assess the Safety and Efficacy of the Combination of Tucatinib and Trastuzumab and Capecitabine for Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer  awarded by Johns Hopkins University 2018 - 2023
  • NN106 Cytochrome C Oxidase Activity In Newly Diagnosed Glioblastoma Multiforme (GBM)  awarded by MASSACHUSETTS GENERAL HOSPITAL 2016 - 2023
  • A Phase I Trial of IRS-1 HSV C134 Administered Intratumorally in Patients with Recurrent Malignant Glioma  awarded by Gateway for Cancer Research (The) 2019 - 2022
  • Oncolytic Immunotherapy Using Chimeric HSV C134: A Phase I Trial and Establishment of Response Indicators in Recurrent Glioma Patients  awarded by National Cancer Institute/NIH/DHHS 2018 - 2021
  • Private Grant  awarded by IMMUNOCELLULAR THERAPEUTICS 2016 - 2021
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2019 - 2021
  • A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of 2 Potential Disease Modifying Therapies in Individuals at Risk for and with Dominantly Inherited Alzheimer’s Disease  awarded by Washington University 2013 - 2020
  • UAB 1764:The Targeted Agent and Profiling Utilization Registry (TAPUR) Study  awarded by American Society of Clinical Oncology 2017 - 2020
  • Targeting PRMT5 in Cancer Initiating Cells as a New Therapy for Glioblastoma  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2015 - 2020
  • Private Grant  awarded by ONCOCEUTICS INC 2019 - 2020
  • Alliance for Clinical Trials in Oncology Payment Agreement  awarded by MAYO CLINIC 2017 - 2020
  • Private Grant  awarded by BOSTON BIOMEDICAL, INC. 2018 - 2020
  • Private Grant  awarded by INCYTE CORPORATION 2015 - 2020
  • A Phase 1 Study of M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma  awarded by National Cancer Institute/NIH/DHHS 2017 - 2020
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2016 - 2020
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2014 - 2020
  • Private Grant  awarded by VASCULAR BIOGENICS LTD 2016 - 2020
  • Private Grant  awarded by MedImmune 2015 - 2020
  • Private Grant  awarded by BIOGEN, INC. 2016 - 2020
  • Decisional Capacity Evaluation in Metastatic Brain Cancer  awarded by American Cancer Society, Inc. 2015 - 2019
  • UAB Center for Clinical and Translational Science (CCTS) (3 Linked Awards UL1, KL2, TL1)  awarded by National Center for Advancing Translational Sciences/NIH/DHHS 2015 - 2019
  • UAB NRG Oncology Master Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2019
  • The Frontotemporal Lobar Degeneration Clinical Research Consortium  awarded by University of California, San Francisco 2016 - 2019
  • Private Grant  awarded by INCYSUS THERAPEUTICS INC. 2019
  • MARCKS as a Novel Regulator of Glioblastoma Growth and Treatment Resistance  awarded by American Cancer Society, Inc. 2014 - 2019
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2017 - 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2015 - 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2014 - 2019
  • Cytochrome C Oxidase: Biomarker In Newly Diagnosed Glioblastoma Multiforme  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2016 - 2018
  • SPRINT-MS: A Randomized Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Activity of Ibudilast (MN-166) in Subjects with Progressive Multiple Sclerosis (NN 102)  awarded by MASSACHUSETTS GENERAL HOSPITAL 2014 - 2018
  • Private Grant  awarded by ABBVIE INC 2017 - 2018
  • Tau PET Imaging for the USC Alzheimer's Therapeutic Research Institute (USC ATRI) A4 Trial (“A4 TAU”)  awarded by University of Southern California 2017
  • Private Grant  awarded by Sanofi US Services Inc 2013 - 2017
  • Private Grant  awarded by IMMUNOCELLULAR THERAPEUTICS 2015 - 2017
  • Advancing Research and Treatment for Frontotemporal Lobar Degeneration [ARTFL]: Research Project 1 & 2  awarded by University of California, San Francisco 2015 - 2017
  • UAB Research and Education Program in Neurology, Neurosurgery, and Neuropathology  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2012 - 2017
  • Refinement and Expansion of the Palliative Care Research Cooperative Group (PCRC)  awarded by Duke University 2017
  • Contemporary Therapeutics for Anaplastic Gliomas  awarded by National Cancer Institute/NIH/DHHS 2011 - 2017
  • Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)  awarded by University of Southern California 2016 - 2017
  • Private Grant  awarded by NORTHWEST BIOTHERAPEUTICS 2015 - 2017
  • COMPLETED - Comprehensive Cancer Center Core Support Grant - Neuro-Oncology Program  awarded by National Cancer Institute/NIH/DHHS 2016 - 2017
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2016 - 2017
  • Alzheimer's Disease Cooperative Study - A4 Study  awarded by University of Southern California 2015 - 2017
  • Private Grant  awarded by NOVOCURE (ISRAEL) LTD 2013 - 2016
  • Private Grant  awarded by GUERBET 2014 - 2016
  • Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH-II): A Phase III Randomized Multicenter Clinical Trail of Blood Pressure Reduction  awarded by University of Minnesota 2014 - 2016
  • Active - Major Program Leader - Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Private Grant  awarded by NOVOCURE, INC. 2014 - 2016
  • A Pilot Phase IIB, Randomized, Multi-Center Trial of Argatroban in Combination with Recombinant Tissue Plasminogen Activator for Acute Stroke (ARTSS-2)  awarded by UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER (HOUSTON) 2014 - 2015
  • UAB Center for Clinical and Translational Science (CCTS) (3 linked awards: UL1, KL2, TL1)  awarded by National Center for Advancing Translational Sciences/NIH/DHHS 2014 - 2015
  • Private Grant  awarded by BRACCO DIAGNOSTICS, INC. 2014 - 2015
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2012 - 2014
  • UAB Center for Clinical and Translational Science (CCTS) UL1  awarded by National Center for Advancing Translational Sciences/NIH/DHHS 2011 - 2014
  • Private Grant  awarded by BRACCO DIAGNOSTICS, INC. 2012 - 2014
  • ACRIN 6684: Phase II Assessment of Tumor Hypoxia in Glioblastoma Using FMISO with PET and MRI (R09-185)  awarded by American College of Radiology 2010 - 2014
  • Private Grant  awarded by Sanofi US Services Inc 2010 - 2013
  • Molecular Therapeutics for Anaplastic Gliomas  awarded by National Cancer Institute/NIH/DHHS 2004 - 2011
  • Education And Training

  • Doctor of Medicine, University of Tennessee System : Memphis 1991
  • National Naval Medical Center, Internship 1992
  • UAB Hospital, Residency 1998
  • National Naval Medical Center, Residency 1995
  • UAB Hospital, Postdoctoral Fellowship 1999
  • Full Name

  • Louis Nabors